CompletedEUCTR 2020-004291-18
Open-label Long-Term Extension Study for Participants With Treatment-Resistant Major Depressive Disorder Who are Continuing Esketamine Nasal Spray Treatment From Study 54135419TRD3013
This historical record does not confirm current site availability.
Historical research recordMultiple countriesDepression
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
- Listed locations
- Belgium · Bulgaria and 6 more locations
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 203
- Sponsor
- Janssen-Cilag International NV
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Belgium, Bulgaria, Czechia, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2020-004291-18
- Official title
Show the full official title
Open-label Long-Term Extension Study for Participants With Treatment-Resistant Major Depressive Disorder Who are Continuing Esketamine Nasal Spray Treatment From Study 54135419TRD3013
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Belgium · Bulgaria · Czechia
5 more locations
- Finland
- Germany
- Greece
- Hungary
- Poland
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Janssen-Cilag International NV.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
